Bayer, Orion prostate cancer drug Daroluramide wins USFDA nod

According to the 2014 deal, Bayer has the right to commercialise daroluramide globally while Orion will manufacture the product and receive milestone payments upon the first sale in different markets.

U.S: Finland's Orion and Germany's Bayer said on Wednesday the U.S. Food and Drug Administration (FDA) had approved prostate cancer drug daroluramide, which the two companies have been developing together. Orion, Bayer prostate cancer drug gets FDA approval

"The compound was approved under the FDA Priority Review designation, which is reserved for medicines that may provide significant improvements in the safety or effectiveness of the treatment for serious conditions," Orion said.

According to the 2014 deal, Bayer has the right to commercialise daroluramide globally while Orion will manufacture the product and receive milestone payments upon the first sale in different markets.

Earlier this year Orion defined darolutamide as its most important growth driver for the next few years and said it was eligible to receive a milestone payment of 45 million euros ($50 million) upon first commercial sales in the United States.

Read Also: Bayer high-precision cancer drug Vitrakvi in frame to receive first EU nod

Orion said Bayer has filed for approval of the compound also in the European Union, Japan and other health authorities.

Read Also: Bayer sells Dr Scholls footcare brand to US firm for USD 585 million